

1 **The reconstitution of body mass index in HIV positive subjects under**
2 **antiretroviral treatment in Kinshasa**

3

4 Guyguy Kabundi Tshima^{1,2,3,4,*}, Paul Madishala Mulumba^{1,+ (deceased)}

5 ¹ Service de Parasitologie, Département de Médecine Tropicale, Maladies Infectieuses et
6 Parasitaires, Faculté de Médecine, Université de Kinshasa, Democratic Republic of the Congo

7 ² Alumnus of the Inter-University Diploma of HIV and AIDS of Ouagadougou University

8 ³ Alumnus of the Faculty of Bioscience Engineering of the Ghent University

9 ⁴ Free Student at the University of Montreal

10 *Correspondence: guyguytshimakabundi@gmail.com (G.K. Tshima)

11 ⁺ deceased

12 **WORD COUNT:** Abstract in English: **224**, in French: **250**, main manuscript: **3, 497**

13

14

15

16

17

18

19 **Abstract**

20 **Objective:**

21 We aimed to evaluate BMI changes in HIV adults' subjects in the first year of ART in malaria
22 endemic areas.

23 **Methods:**

24 We used linear regression analysis showing that the change in weight at 12 months (y) in a
25 malaria-endemic area is related to malaria infection at admission and its different episodes as
26 illustrated by equation: $y = a + bxi + \epsilon$, where x is malaria on admission, i refers to episodes of
27 clinical malaria infection during the year, b is the slope, a is a constant and ϵ are confounding
28 factors such as tuberculosis or poor eating habits.

29 **Results:**

30 We found a positive value for b ($b = 0.697$), and this shows that weight loss at 12 months is
31 correlated with the diagnosis of severe malaria at admission. In other words, severe malaria
32 eliminates the weight gained under ART.

33 **Conclusions:**

34 1. Malaria is the leading cause of weight loss under ART.

35 2. Important recommendation for future:

36 This study suggests nutritional education based on local foods containing antioxidants to fight the
37 oxidative stress generated by HIV and stimulated by *Plasmodium falciparum* during febrile
38 episodes. Oxidative stress is blocked by NADPHase which is a metalloenzyme based on
39 selenium.

40 Thus, to prevent a weight loss or the occurrence of the protein-energy malnutrition among people
41 living with HIV, it is necessary to use the nutritional education.

42 **Résumé**

43 **Objectif:**

44 Nous voulions évaluer les modifications de l'IMC chez les patients VIH adultes au cours de la
45 première année du traitement antirétroviral dans une zone d'endémie palustre

46 **Matériel et Méthodes:**

47 Nous avons utilisé une analyse de régression linéaire montrant que la variation de poids à 12
48 mois (y) dans une zone d'endémie palustre est liée à l'infection palustre à l'admission et à ses
49 différents épisodes, comme l'illustre l'équation suivante: $y = a + bxi + \epsilon$, où x est le paludisme à
50 l'admission, i les épisodes de paludisme clinique survenus au cours de l'année, b est la pente, a
51 est une constante et ϵ sont des facteurs de confusion tels que la tuberculose ou de mauvaises
52 habitudes alimentaires..

53 **Résultats:**

54 Nous avons trouvé une valeur positive pour b ($b = 0,697$), ce qui montre que la perte de poids à
55 12 mois est en corrélation avec le diagnostic de paludisme grave à l'admission. En d'autres
56 termes, le paludisme grave élimine le poids gagné sous traitement antirétroviral.

57 **Conclusions:**

- 58 1. Le paludisme est la principale cause de perte de poids sous ARV.
- 59 2. Recommandation importante pour l'avenir : Cette étude suggère une éducation nutritionnelle
60 basée sur des aliments locaux contenant des anti-oxydants pour lutter contre le stress oxydatif
61 généré par le VIH et stimulé par le *Plasmodium falciparum* lors des poussées fébriles. Le stress

62 oxydatif est bloqué par la NADPHase qui est une métalloenzyme à base de sélénium. Ainsi, il est
63 nécessaire d'utiliser l'éducation nutritionnelle pour prévenir la perte du poids sous ARV.

64

65 **Introduction**

66

67 For the investigation on weight evolution under ART in case of malaria being reported,
68 worldwide in 2016, there were 36.7 million people living with HIV [1]. And in 2015, there were
69 an estimated 214 million cases of malaria worldwide, and an estimated 438 000 deaths [1].
70 Approximately 90% of all malaria deaths occur in Africa [2]. Since 2011 there was no WHO
71 recommendation regarding any specific antimalarial treatment (AMT) for patients living with
72 HIV in malaria areas [3], there is a need to explore the possibility of establishing specific
73 guidelines for this category of patients co-infected with *Plasmodium falciparum*. The present
74 work deals with the pending situation of co-infection HIV-malaria which remains a major public
75 health problem in several countries worldwide [3].

76 A first step towards the physiopathology of the weight loss during the co-infection severe
77 malaria-HIV because due to co-infection, the metabolic demands of antioxidant products such as
78 selenium, vitamin C and vitamin E are increased. As a result, micronutrient deficiencies increase
79 due to malaria and HIV [4].

80 The mechanisms of HIV oxidative stress and malaria progression can be explained in two ways:
81 first, malaria stimulates NADPHase blocked by antiretroviral therapy, exposing the patient to
82 weight loss, and elsewhere it has been shown that HIV-positive people and those infected with

83 malaria suffer from an oxidative / antioxidant imbalance [5]. Therefore, establishing the
84 physiological balance between oxidants and antioxidant factors is of great therapeutic interest.

85 In this context, the implication of the present study is to evaluate the impact of severe malaria on
86 weight change and the perspective is to design a nutrient (Selenium) that can help strengthen the
87 immune state of HIV+ subjects to fight HIV-induced oxidative stress and *Plasmodium*
88 *falciparum* during severe AIDS-malaria co-infection [6].

89 We expected dietary intake using local foods rich in antioxidants. A first step towards our
90 research began with foods inquiry when in 2007, according to an American work, the daily intake
91 of Selenium in the form of food supplements could even reduce the viral load in patients with
92 HIV: a study of 262 patients, the antioxidant properties of Selenium would be responsible for this
93 decrease. "An explanation that required confirmation," said the author [7]. Anyway, it was an
94 interesting thought trail. "Selenium supplementation is a simple, safe and inexpensive approach"
95 [7]. Not to mention that to refill Selenium, there are other solutions than the use of food
96 supplements e.g. Seafood, Mushrooms. It would thus protect against cardiovascular diseases but,
97 also, against certain digestive cancers [7] .

98 Several international works lend it interesting properties:

99 - Several investigators have found that HIV-infected patients have a compromised antioxidant
100 defense system. Blood antioxidants are decreased, and the products of lipid and protein oxidation
101 are increased in these patients. This may have physio pathological implications [8] ;

102 - Selenium supplementation affects specific populations of T lymphocytes and decreases the
103 markers of lipoperoxides [9] ;

104 - Selenium plays an important role in the maintenance of immune function and neutralizes the
105 superoxide ions produced by activated macrophages and neutrophils in response to the aggression
106 of the body by microorganisms [10] .

107 So, the progression of HIV infection to the AIDS stage is due to the production of free radicals. It
108 would be interesting to identify possible mechanisms and clinical trials to evaluate the effect of
109 Selenium supplementation in the progression of HIV infection. The oxidative stress causes the
110 production of cytokines that lead to cachexia [11] .

111 This study focuses on the reconstitution of weight in HIV positive patients under antiretroviral
112 treatment (ART) in the environment of Kinshasa where patients living with HIV are combining
113 the antiretroviral treatment (ART) and the antimalarial treatment (AMT) when they are diagnosed
114 malaria positive with microscopy. The rationale for this study is to describe why they lose weight
115 with a good observance on ART. What is the exposure factor?

116 **Methods and findings**

117 **Data collection**

118 We obtained weight, the individual CD₄ count and the diagnosis of severe malaria among adults
119 in the Democratic Republic of the Congo using the 2007 AMOCONGO Kinshasa-Kasavubu
120 Register HIV database. The AMOCONGO Kinshasa-Kasavubu 2007 database is a routinely
121 collected health data which a product of the daily operations of the healthcare centre are collected
122 independently of specific a priori research questions. The use of health data routinely collected in
123 a prospective view is explained in those studies following the RECORD-PE [12-30]

124 **Ethical issues**

125 The University of Kinshasa ethic committee and the National Programme of AIDS estimated
126 ethic to use the health data sampling in AMOCONGO Kinshasa-Kasavubu Register.

127 **BMI**

128 BMI is calculated using weight (kg) divided by squared height (m²). Weight and height were
129 directly measured by AMOCONGO medical staff. Since our targeted samples are adults, we do
130 not expect any significant variation in the height for twelve months that could affect the BMI.
131 Therefore, only the change in weight is considered as a parameter that can be evaluated in the
132 evolution of BMI. So, we replaced BMI by weight. Weight was reported as usual at the
133 admission, at 3 months, at 6 months and at 12 months.

134 **Adequate logistic regression model**

135 Using Minitab software, we compute the binary logistic regression after the regression,
136 confusion, and interaction assumptions. The probabilities greater than 5% means that the model is
137 adequate.

138 **Limitations**

139 The following were limitations:

- 140 • Malaria access: only 1 or repeated access (HIV infection potentiates the frequency of
141 access), it was necessary to distinguish between severe malaria and simple malaria
- 142 • The different ART regimes: Triomune-30, Triomune-40, Kaletra, ... It is known that
143 certain molecules are leading to more resistance than others.
- 144 • The different antimalarial drugs used and antimalarial combinations: Quinine,
145 Sulfadoxine-Pyrimethamine, Artesunate-Amodiaquine, Artemether-Lumefantrine, ...

- 146 • Nutritional education: distinguish between patients who have attended a nutrition
147 education course and others who have not.
- 148 • Antibiotherapy: duration and frequency of treatment
- 149 • The date of last taking deworming medication: undernutrition can be controlled by
150 intestinal worms (*Ascaris*, *Anguillules*, *Trichocephales*, ...). It would be interesting to note
151 whether a stool examination was done or not
- 152 • Alcohol: plays an important role in the accumulation of fats
- 153 • Tobacco: makes you lose weight; distinguish between smokers and non-smokers
- 154 • HIV serologic status: consider the control group (HIV-)
- 155 • Marital status: married couples can have a regular diet compared to singles)
- 156 • ART duration: 3 months were sufficient to evaluate the recovery of the body mass index?
- 157 • CD4 lymphocyte count: broadly divided into two groups
- 158 * Normal CD₄ level ≥ 200
- 159 * Low CD₄ rate ≤ 200 : those are put on ART
- 160 - Associated opportunistic pathologies
- 161 • Social standing
- 162 • Age: Adults, the ideal would be to resort to children in vaccination period (0-5 years) to
163 limit the confounding factors
- 164 • Number of CD₄ count for HIV-negative adults: we did not have data on the enumeration
165 of CD₄ lymphocytes for HIV-negative adults.

166

167

168

169

170

171

172

173

174

175

176

177 **Results**

178

179 **Descriptive data**

180 **Demographic characteristics of study participants**

181 Table 1 shows baseline characteristics of the Congolese adults.

182

Age in years (n = 72)	Percentage	Mean (SD)
21 < 29 years (n=22)	30.7%	32.6 (11.6)
30-49 years (n =23)	32.1%	
50-59 years (n=27)	37.2%	
≥60 years (n = 0)	0%	

183

184

Table 1. Sample characteristics, age distribution.

185 The final sample included 72 individuals, which expanded to 72 adults with 22 young adults 21

186 to 29 years old, in comparison to adults of 30 to 49 years old, of 50 to 59 years old. The average

187 age was 32.6 years (11.6). 37.2% (50-59 years) was the highest percentage; this means that
188 experienced people are the most infected with HIV-AIDS. This is really a problem for a
189 developing country like the DRC that needs experienced adult workers for its development.

190 Table 2 shows that the sex ratio was 4 women to 1 man. Apart from the biological reasons that
191 would explain that the female genital area is larger than the male one and explain the
192 vulnerability of the latter in unprotected sex. It is meanly meaning that Congolese women seek
193 more help from health facilities than men for cultural reasons. Men want to see themselves strong
194 and therefore not vulnerable to disease. Sick Guards are women most of the time, and for prenatal
195 or pre-school clinics, women are more likely to attend the hospital than men. Congolese men
196 refuse to ask for help in the first symptoms of the disease, they first want to fight alone so,
197 logically with a weakened body the expected mortality rate should be higher in men than in
198 women because they will be treated later, with the higher risk of death following the natural
199 course of the disease.

200

Sex (n _{total} =72)	Percentage (n _{total} =72)
Men (n=15)	21% (n/n _{total})
Women (n=57)	79% (n/n _{total})

201

202

Table 2. Repartition of sex

203

204

Significance of logistic regression model after analysis of health data

205 Table 3 showed a p-value > 0.05, at this level we cannot draw a conclusion because it has no
206 scientific value, so we did linear regression to try to show a correlation between the effect of
207 severe malaria on the number of CD₄ and the decrease in weight. Due to the binary logistic

228 **Linear regression model: highlighted how was the exclusive effect of severe**
229 **malaria**

230 According to our statistical results, we have retained only 2 variables: response variable (Y) =
231 Initial weight-Weight at 12 months; Predictive variable 1 (X_1) = diagnosis of severe malaria.
232 Finally, the equation retained was: $Y = a + b_1X_1$

233 **The Retained Predictor variable**

234 Table 5 shows the retained predictive variable. We made our decision at an $\alpha = 0.05$ level of
235 significance i.e. if the p-value is <0.05 , we reject the null hypothesis and otherwise we keep it.
236 Since p is still very weak ($p = 0.00005$), the conclusion of a positive linear relation was even be
237 declared very strongly.

238

239

240

Predictor	P	Null Hyp	Decision	Conclusion
Constant	0.011	$\beta_0=0$	Retain H_0	The constant appears to be zero. Even so, we leave it in the model
Severe malaria	0.00005	$\beta_1=0$	Reject H_0	Severe malaria infection at admission can significantly contribute to explain the weight lost at 12 months

241

242

Table 5. Retained predictor variable.

243

244 **Retained predictor variable: severe malaria**

245 The regression equation was: weight loss at 12 months = 15.3 + 0.697 diagnosis of severe
246 malaria. We can use it for estimation purposes: we found $y = 15.3 + 0.697X$ i.e. through linear
247 regression the weight at the admission and 12 months was correlated with the effect of severe
248 malaria.

249 **Interpreting the Linear Regression Model after consulting health data**

250 The interpretation of the model is as follows: for each episode of severe malaria, the weekly
251 averages of weight loss are in the order of 0.697 kg. Based on these forecasts of a weekly weight
252 loss of 0.697 kg with a severe malaria episode, clinicians need to think what to suggest
253 compensating for this, for us we suggest the maize, sorghum and soy.

254 There are correlations between the weight loss at 12 months under ART and the diagnosis of
255 severe malaria on admission. $R = 61.7\%$ i.e. > 50%: this means that the variables explain the
256 model at 61.7%. So, the model is good. The equation is a good predictor.

257

258 **Correlation between weight at 12 months on ART and severe malaria at**
259 **admission**

260 Table 6 showed the correlation between weight at 12 months on ART and severe malaria on
261 admission. We see how the constant is 15,288 and the slope b is = 0.6973, this is the coefficient
262 of severe malaria. In this case, because our p-value is <0.05 (Table 4), we confirm that there is a
263 correlation between weight at 12 months on ART and severe malaria on admission. And how to
264 say that we have a good model for the prediction? It is by the coefficient of determination R^2 . The

265 coefficient of determination $R^2 = 0.617$. Thus, only about 62% of the total variability in weight
266 loss at 12 months under ART in the sample is explained by the linear regression relationship
267 following energy expenditure because of severe malaria on the weight.

268

Predictor	Coef	SE Coef	T	P
Constant	15.288	5.624	2.72	0.011
Severe malaria infection	0.6973	0.1003	6.95	0.00005

269

270

Table 6. Analysis of table of coefficients of linear regression.

271

272 This example illustrates that there is no contradiction in finding other variables that contribute to
273 weight loss called predictive variables X_i , i.e.: X_1 = severe malaria; X_2 = Weight on admission; X_3
274 = $CD_4 / \mu l$; X_4 = co-infection HIV / severe malaria, $X_{i+j} = (5)$ diabetes, (6) cirrhosis, (7)
275 tuberculosis, (8) cancer, (9) age, (10) poverty, (11) poor nutritional status, (12) helminths, etc.

276 From 9, 10, 11 predictive variables, there is really a conceptual problem to include all of them in
277 the model.

278

279

280 **Consequence of such situation**

281 One consequence of such a situation may be that clinicians should prevent episodes of malaria in
282 HIV + patients living in malaria endemic areas.

283 **Analysis of variance for the four moments of weight measurement: 0, 3, 6 and 12** 284 **months**

285 ANOVA was used to check for significant differences in variables and in different time periods.
286 The significant level was set at $p < 0.05$. Table 7 shows that the probability (0.591) is greater than
287 0.05; there is therefore no significant difference between the average of four weights. Using
288 ANOVA, we find that the four means of weight were not significantly different.
289

Source	DF	SS	MS	F	P
Regression	3	129.15	43.05	0.64	0.591
Residual Error	124	8350.46	67.34		
Total	127	8479.61			

290 **Table 7. Analysis of variance for the four moments of weight measurement: 0, 3, 6 and 12**
291 **months**

292

293 **Confounding factors**

294 Not evaluated: The role of poverty and bad nutritional status as confounding factors, the role of
295 other dysimmunities comorbidities (diabetic, cirrhose...).

296 **83% of patients have not seen their weight increase**

297 This is what was observed in the health data consulted, which underlines the need for a
298 supplement and other antimalarial measures, lifestyle, diet following the second specific
299 objective.

300 **Repetition of malaria episodes based on the number of CD4 / μ l at admission**

301 In sum, there is no statistically significant interaction of the diagnosis of severe malaria on the
302 number of CD₄ <50 cells / μ l on admission, although it has been observed in some individual
303 cases.

304 **The effect of clinical malaria infection on weight**

305 Based on our example of 72 observations, we make predictions of the effect of clinical malaria
306 infection on weight.

307 We identified more than 7 episodes of severe malaria (30%) and a CD₄ count <50 cells / μ l in the
308 subgroup whose weight did not increase in the first year under ART.

309 The other subgroup whose subjects had gained weight in 12 months under ART had 5% of severe
310 malaria attacks and a CD₄ count > 50 cells / μ l. CD₄ with less than 7 malaria episodes per year.

311 HIV infection increases the repetition of clinical malaria episodes, which could be associated
312 with weight loss.

313 Our results emphasized that the accurate assessment of the effect of clinical malaria on HIV-
314 infected people is limited by the lack of rigorous diagnostic criteria and the definition of what
315 may be considered malaria.

316 If the thick-film had been made and was a test with the highest sensitivity-specificity and number
317 of parasites / μ l of blood, patients could have a parasitaemia that coincides with the fever of

318 another origin (such as opportunistic infections, bacterial diseases such as *Streptococcus*
319 *pneumoniae*, *Salmonella typhi* species or not).

320 **Discussion**

321

322 **Key results with reference to study objectives**

323 The health data from a sample of 72 participants of AMOCONGO Kinshasa Kasavubu HIV
324 Register show overall, in the whole group (including the HIV + subgroup whose weight did not
325 increase in the first year on ART and the subgroup who gained weight), the ANOVA admission,
326 at 3 months, at 6 months and at 12 months later the four weight averages are not significantly
327 different. So, there is on average no significant weight change in the first year under ART. We
328 conclude that severe malaria is the cause of weight loss and should be controlled by the
329 preventive treatment of malaria. Whence continuous treatment of malaria in a HIV positive
330 subject (with therapeutic antimalarials intermittent treatment) will help prevent weight loss by
331 decreasing the parasite biomass buried in the deep organs (liver, spleen, brain, kidney) therefore
332 not detectable at the peripheral level with the examination of the thick drop.

333 **Outcomes of the study**

334 The present study aimed to determine the relationship between severe malaria and HIV among
335 HIV+ adults living in malaria endemic area as Kinshasa in the Democratic Republic of the Congo
336 and their clinic expression in the weight loss. About malaria definition based on clinical signs,
337 this study is in conformity with Flateau [3] and Rogier [32]: Flateau affirms that because of the
338 absence of malaria rigorous diagnostic criteria, the precise evaluation of the effect of malaria in
339 HIV-infected patients is limited [3]. Rogier said that it is difficult to define malaria although its
340 epidemiological data are known [32]. For us the rigorous diagnostic criteria are a positive
341 microscopic test before treatment and the disappearance of admissions symptoms after the AMT

342 as we stated that malaria is a retrospective diagnosis using health data. It means that when a
343 person presents malaria symptoms you never know if it's malaria or not. It is only after the
344 treatment that you'll get the answer because of co-infections.

345 According to the malaria management our study agrees to wait for microscopy results before
346 starting the treatment. We found for 10 years (2000-2009) only 32% of malaria positives samples
347 in a study that we evaluated in Kinshasa University Hospital about malaria microscopic diagnosis
348 [35]. For us in area of high endemicity of malaria, a treatment should begin with a serious sign as
349 fever (39-40°C), positive microscopic test and anemia that may be malaria for an adult with HIV
350 living in high malaria endemicity area. Although if the microscopic test is negative, the fever can
351 have another origin such as bacterial diseases particularly tuberculosis, *Streptococcus pneumoniae*,
352 non-typhi Salmonella species and other opportunistic diseases.

353 As the malaria mortality is increasing with the severity of immunosuppression (low CD cells / μ l)
354 [3], this study suggests treating malaria if CD₄<50 cells / μ l in malaria area with clinical signs and
355 malaria microscopic positive test according to our observation of the health data. We chose our
356 sample based on physician's diagnosis made with severe malaria symptoms as fever and anemia.
357

358 **Malaria episodes and HIV infection**

359 The present study identified more than 7 episodes (30%) of severe malaria with a number of
360 CD₄<50 cells/ μ l in the sub-group who lost weight in the first year of ART. The other subgroup
361 who gains weight had 5% of 1 to 7 malaria episodes. In Nigeria Amuta observed that in people
362 living with HIV and AIDS, the prevalence of malaria was low when CD₄ counts increased and it
363 was increased when CD₄ was low [31]. In a prospective study in South Africa, HIV-infected

364 people had an increased risk of severe malaria by 4 times, and the prevalence of severe malaria
365 was the highest when the CD₄ cell count was less than 200 cells per μ l [3]. In subgroup analyses,
366 HIV infection was associated with an increased risk of severe malaria in non-immune, but not in
367 semi-immune people [3].

368 **Conceptual Model □ on the associations between malaria, HIV and weight** 369 **changes**

370 The conceptual model explains the physiopathology of the co-infection HIV-MALARIA. In one
371 hand malaria stimulate the NADPHase blocked by the ART making that a HIV+ people under
372 ART can lose weight during malaria crisis. In the other hand the key of that physiopathology is
373 relative to the endothelium equilibrium to establish between oxidants and anti-oxidants factors as
374 selenium in the cellular level.

375 **Therapeutic nutrition**

376 In view of the above, we recommend that therapeutic nutrition be included in the overall strategy
377 to combat HIV-*Plasmodium* co-infection.

378

379

380 **Conclusions**

381 Based on these forecasts of a weekly weight loss of 0.697 kg with a severe malaria episode, we
382 suggest the consideration of the NADPH oxidase in the physiopathology of the co-infection HIV-
383 malaria for therapeutic relevance using local foods rich in Selenium. Excluding other variables,
384 malaria is the main cause of weight loss under ART in Kinshasa. We found that health data that
385 reports longitudinal data adhere to generally accepted Prospective Study definition.

386 **Declaration of conflict of interest**

387 None

388 **Acknowledgments**

389 None.

390

391 **References**

392

393 1. Dolan K., Wirtz A.L., Moazen B., Ndeffo-Mbah M., Galvani A., Kinner S.A., Courtney R.,
394 McKee M., Amon J.J., Maher L., Hellard M., Beyrer C., Altice F. Global burden of HIV,
395 viral hepatitis, and tuberculosis in prisoners and detainees. *Lancet* 2016, Vol: 388, Issue:
396 10049, Page: 1089-1102. Google scholar

397 2. Hemingway J., Ranson H., Magill A., Kolaczinski J., Fornadel C., Gimnig J., Coetzee M.,
398 Simard F., Roch DK., Hinzoumbe CK, Pickett J., David Schellenb D., Peter Gething, Mark
399 Hoppé, Nicholas Hamon. Averting a malaria disaster: will insecticide resistance derail
400 malaria control? *Lancet* 2016; 387: 1785–88. Google scholar

401 3. Flateau CG., Le loup G. et Pialoux G. Consequences of HIV infection on malaria and
402 therapeutic implications: a systematic review. *Lancet Infect Dis.* 2011;11:541-56. Google
403 scholar

404 4. Orish VN. *et al.* The effects of malaria and HIV co-infection on hemoglobin levels among
405 pregnant women in Sekondi-Takoradi, Ghana. *International Journal of Gynecology and*
406 *Obstetrics.* 2013;120:236-239. Google scholar

- 407 5. Osuji FN. *et al.* Antioxidant activity in HIV and malaria co-infected subjects in Anambra
408 State, southeastern Nigeria. *Asian Pacific Journal of Tropical Medicine.* 2012 ; 842-847.
409 Google scholar
- 410 6. Tshima KG, Mulumba MP, Odio WT, D'Haese L, Remaut Dewinter A.M. Nine months
411 supplementation with Selenium and nutrition education for people living with HIV/AIDS in
412 Democratic Republic of Congo, PhD Project, Ghent University, 2007
- 413 7. <http://fr.news.yahoo/22012007/185/quand-lanutrition-aide-combattre-le-vih.html>.
- 414 8. Fuchs J, Schöfer H, Milbradt R, Freisleben HJ, Buhl R, Siems W, Grune T. Studies on lipoate
415 effects on blood redox state in human immunodeficiency virus infected
416 patients. *Arzneimittelforschung.* 1993;43(12):1359-62. Pubmed
- 417 9. Patrick L. Nutrients and HIV: part one -- beta carotene and selenium. *Altern Med Rev.* 1999
418 ;4(6):403-13. Pubmed
- 419 10. Constans J, Delmas-Beauvieux MC, Sergeant C, Peuchant E, Pellegrin JL, Pellegrin I, Clerc
420 M, Fleury H, Simonoff M, Leng B, Conri C. One-year antioxidant supplementation with beta-
421 carotene or selenium for patients infected with human immunodeficiency virus: a pilot
422 study. *Clin Infect Dis.* 1996 ;23(3):654-6. Pubmed
- 423 11. Baum MK, Shor-Posner G. Micronutrient status in relationship to mortality in HIV-1
424 disease. *Nutr Rev.* 1998 ;56(1 Pt 2): S135-9. Pubmed
- 425 12. Langan SM, Schmidt SAJ, K Wing, V Ehrenstein, SG Nicholls, KB Filion, O Klungel, I
426 Petersen, HT Sorensen, WG Dixon, A Guttman, K Harron, LG Hemkens, D Moher, S
427 Schneeweiss, L Smeeth, M Sturkenboom, E von Elm, SV Wang, EI Benchimol. The reporting of
428 studies conducted using observational routinely collected health data statement for
429 pharmacoepidemiology (RECORD-PE) *BMJ* 2018;363: k3532. Google Scholar

- 430
431 13. Benchimol EI, Smeeth L, Guttman A, et al, RECORD Working Committee. The REporting
432 of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.
433 *PLoS Med* 2015;12:e1001885. 10.1371/journal.pmed.1001885. Google scholar
- 434 14. Spasoff R. *Epidemiologic methods for health policy*. Oxford University Press, 1999. Google
435 scholar
- 436 15. Mor A, Petersen I, Sørensen HT, Thomsen RW. Metformin and other glucose-lowering drug
437 initiation and rates of community based antibiotic use and hospital-treated infections in patients
438 with type 2 diabetes: a Danish nationwide population-based cohort study. *BMJ Open*
439 2016;6:e011523. 10.1136/bmjopen-2016-011523. Google scholar
- 440 16. Nørgaard M, Johnsen SP. How can the research potential of the clinical quality databases be
441 maximized? The Danish experience. *J Intern Med* 2016; 279:132-40. doi:10.1111/joim.12437.
442 Google scholar
- 443 17. <http://www.chups.jussieu.fr/poly/biostats/poly/POLY.Chp.15.4.html> consultation of
444 28/10/2015
- 445 18. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Current use of routinely collected
446 health data to complement randomized controlled trials: a meta-epidemiological survey. *CMAJ*
447 *Open* 2016;4:E132-40.doi:10.9778/cmajo.20150036
- 448 19. Moher D, Glasziou P, Chalmers I, et al. Increasing value and reducing waste in biomedical
449 research: who's listening? *Lancet* 2016;387:1573-86. doi:10.1016/S0140-6736(15)00307-4
- 450 20. Canadian Institutes of Health Research. *Canada's strategy for patient-oriented research.*
451 *Improving health outcomes through evidence informed care*. Canadian Institutes of Health
452 Research, 2011.

- 453 21. Hoffman S, Podgurski A. The use and misuse of biomedical data: is bigger really better? *Am*
454 *J Law Med* 2013;39:497-538.doi:10.1177/00988588130390040
- 455 22. Cohen IG, Amarasingham R, Shah A, Xie B, Lo B. The legal and ethical concerns that arise
456 from using complex predictive analytics in healthcare. *Health Aff (Millwood)* 2014;33:1139-47.
457 doi:10.1377/ hlthaff.2014.0048
- 458 23. Benchimol EI, Manuel DG, To T, Griffiths AM, Rabeneck L, Guttman A. Development and
459 use of reporting guidelines for assessing the quality of validation studies of health administrative
460 data. *J Clin Epidemiol* 2011; 64:821-9. doi: 10.1016/j.jclinepi.2010.10.006
- 461 24. Hemkens LG, Benchimol EI, Langan SM, et al. The reporting of studies using routinely
462 collected health data was often insufficient. *J Clin Epidemiol* 2016; 79:104-11. doi:10.1016/j.
463 jclinepi.2016.06.005
- 464 25. Wang SV, Verpillat P, Rassen JA, Patrick A, Garry EM, Bartels DB. Transparency and
465 reproducibility of observational cohort studies using large healthcare databases. *Clin Pharmacol*
466 *Ther* 2016; 99:325- 32. doi:10.1002/cpt.329
- 467 26. Nzongola-Ntaladja G. The Congo from Leopold to Kabila: A People's History. In *AIDS in*
468 *Africa*; 2002. Google scholar
- 469 27. Brittain V. Calvary of the women of Eastern Democratic Republic of Congo. In *HIV and*
470 *AIDS in Africa*; 2002. Google scholar
- 471 28. Aminake MN. et al. Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-
472 malaria combination therapy. *Bioorg. Med. Chem.* 2012; 20:277-5289. Google scholar
- 473 29. Van Geertruyden JP., Mulenga M., Mwananyanda L. et al. HIV-1 immune suppression and
474 antimalarial treatment outcome in Zambian adults with uncomplicated malaria. *J Infect Dis.*
475 2006; 194: 917. Google scholar

- 476 30. Mermin J., Ekwaru JP., Liechty CA., et al. Effect of co-trimoxazole prophylaxis, antiretroviral
477 therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in
478 Uganda: a prospective cohort study. *Lancet*. 2006; 367:1256–1261. Google scholar
- 479 31. Amuta EU., Houmsou RS., Diya AW. Malarial infection among HIV patients on
480 antiretroviral therapy (ART) and not on ART: a case study of Federal Medical Centre Makurdi,
481 Benue State, Nigeria. *Asian Pacific Journal of Tropical Biomedicine* 2012: S378-S381. Google
482 scholar.
- 483 32. Rogier C. , Salet G. Modélisation du paludisme. *Med Trop* 2004 : 64 :89-97. Google scholar
- 484 33. Basto-Abreu A, Braverman-Bronstein A, Camacho-García-Formenti D, Zepeda-Tello R,
485 Popkin BM, Rivera-Dommarco J, et al. (2018) Expected changes in obesity after reformulation to
486 reduce added sugars in beverages: A modeling study. *PLoS Med* 15(10): e1002664. [https://doi.](https://doi.org/10.1371/journal.pmed.1002664)
487 [org/10.1371/journal.pmed.1002664](https://doi.org/10.1371/journal.pmed.1002664)
- 488 34. Thas O., Applied Statistics for the food sciences, Faculty of agricultural and applied
489 biological sciences, Department of Applied Mathematics, Biometrics and Process Control, Ghent
490 University. 2006.
- 491 35. Tshima KG. Bio-distribution of *Plasmodium* in Kinshasa: Experience of the Unit of
492 Parasitology of the University Hospital of Kinshasa, Dissertation, 2010.